EU MDR Notified Body Capacity Crisis 2026–2027: 2026 Survey Data, Certification Bottlenecks, and What Manufacturers Must Do Now

The Numbers Tell an Uneasy Story

The European Commission's 18th Notified Bodies Survey, published in March 2026 with data through October 2025, reveals a regulatory system under acute stress. On the medical device side, 33,175 applications have been submitted to Notified Bodies, but only 17,549 MDR certificates have been issued. On the IVD side, the gap is proportionally wider: 3,634 applications against 2,194 IVDR certificates.

The gap between applications submitted and certificates issued leaves an estimated 15,000+ applications still in the pipeline across 51 active Notified Bodies — a volume that cannot keep pace with the number of devices requiring new CE marking to remain legally on the EU market.

The arithmetic is unforgiving. Notified Bodies report that the average time for a successful MDR certification review is 13 to 18 months. For complex devices, it can be longer. Manufacturers who submit applications today face review completion dates in mid-to-late 2027, at the earliest. And thousands of legacy devices still need to transition from the old MDD/AIMDD/IVDD directives to MDR and IVDR before transition deadlines expire.

This is not a theoretical risk. It is an operational, commercial, and strategic crisis that threatens EU market continuity for thousands of medical devices.

What the 2026 Survey Data Shows

MDR Certification Status

The gap between applications and certificates reflects several structural factors:

• Notified Body capacity has increased but remains insufficient for the volume of devices requiring certification
• Application quality varies widely — incomplete submissions and missing documentation remain the most frequently cited problems
• Device misclassification leads to delays and additional review rounds
• Administrative and procedural errors compound review timelines

IVDR Certification Status

The IVDR situation is more severe than MDR. Legacy IVD devices still dominate the EU market, and the transition to IVDR is far less advanced. The Notified Body infrastructure for IVDs was never designed to handle the volume of devices now requiring IVDR conformity assessment.

Growth Trend

The survey shows MDR certificates up 18% and IVDR certificates up 23% from the June 2025 snapshot. This improvement is real, but absolute numbers remain critically low. The rate of certificate issuance, even with growth, cannot close the gap before transition deadlines.

Critical Deadlines Creating the Bottleneck

IVDR Class C Deadline — May 26, 2026

This is the most immediate deadline. Conformity assessment applications for Class C IVDs under legacy IVDD certificates must be submitted to a Notified Body by May 26, 2026. A signed Notified Body agreement is then required by September 26, 2026.

This affects:

• Infectious disease assays
• Companion diagnostics
• Genetic tests
• Self-testing IVDs classified as Class C

Manufacturers that have not yet engaged a Notified Body are running out of time. Without a signed application by May 26, products risk losing legal market access in the EU.

EUDAMED Mandatory — May 28, 2026

Two days after the IVDR Class C deadline, EUDAMED becomes mandatory on May 28, 2026. This is not directly a certification deadline, but it adds significant operational burden to manufacturers already stretched by certification work. Four EUDAMED modules become mandatory:

1. Actor Registration (SRN requirement)
2. UDI and Device Registration
3. Notified Bodies and Certificates
4. Market Surveillance

MDR Transition Deadlines

The Recertification Problem

Even manufacturers who have already obtained MDR certificates face a new bottleneck: recertification. MDR certificates have a maximum validity of five years. The first wave of MDR certificates, issued in 2021–2022, will need renewal starting in 2026–2027. MedTech Europe has warned that recertification could create "a new major bottleneck" as Notified Bodies must process renewals alongside new applications.

Why Applications Get Stuck

The survey identifies specific reasons why submissions fail to progress through the review pipeline:

1. Incomplete Submissions

The most frequently cited problem. Manufacturers submit technical documentation that is missing critical sections, references outdated standards, or fails to address all applicable MDR/IVDR requirements. Notified Bodies must then issue clarification requests, adding weeks or months to the review timeline.

2. Device Misclassification

Incorrect classification leads to the wrong conformity assessment pathway being followed. When the Notified Body identifies a classification error, the manufacturer must restart the process with corrected documentation — effectively beginning the review again.

3. Inadequate Clinical Evidence

Particularly for Class IIb and III devices, clinical evidence packages that would have been acceptable under the MDD often fall short of MDR expectations. The MDR's clinical evaluation requirements (Article 61 and Annex XIV) are substantially more demanding, and many manufacturers underestimate the gap.

4. Post-Market Surveillance Documentation

The MDR requires comprehensive post-market surveillance (PMS) plans, periodic safety update reports (PSURs), and post-market clinical follow-up (PMCF) plans as part of the technical documentation. Many submissions include generic PMS plans that Notified Bodies reject as insufficient.

5. Quality Management System Gaps

Manufacturers must demonstrate that their QMS meets the MDR's requirements, not just ISO 13485. Gaps in regulatory strategy procedures, UDI management, and economic operator oversight frequently trigger additional review rounds.

The EU Commission's Response: Targeted Revisions

On December 16, 2025, the European Commission published a 170-page proposal for targeted revisions to the MDR and IVDR (COM(2025) 1023). The proposal directly addresses the capacity crisis with several structural changes:

Certificate Validity Reform

The current five-year maximum certificate validity would be removed. Certificates would generally not be limited in time, though Notified Bodies could set validity periods based on justified, device-specific grounds. Periodic reviews would be proportionate to risk class.

Risk-Based Surveillance

For many Class IIb and III devices, the five-year recertification cycle would be replaced with annual surveillance audits permitted to extend to 24-month intervals when justified.

Reduced Notified Body Scope

The assessment of technical documentation would be reduced to one representative device per category or generic device group for Class IIa/IIb medical devices and Class B/C IVDs. Remote audits would be explicitly permitted as an alternative to on-site audits.

Structured Dialogue and Dispute Resolution

The revisions formalize "structured dialogue" between manufacturers and Notified Bodies and introduce an "ombudsperson" mechanism for resolving disputes, with a 90-day resolution timeline.

Classification Rule 11 Changes

The proposal restructures how software classification is determined under Rule 11, potentially enabling more medical device software to qualify as Class I (removing the Notified Body requirement), though experts differ on the practical impact.

Timeline

The proposal is in its consultation phase (feedback open until May 6, 2026). Adoption by the European Parliament and Council is expected around Q2 2027 at the earliest, with implementation following thereafter. Manufacturers should monitor the legislative process but not rely on revisions to resolve their immediate certification needs.

Manufacturer Action Plan

If You Have Not Yet Applied

Priority: Immediate action required.

1. Select a Notified Body now. Do not wait for the "perfect" NB. Capacity is the constraint, and the queue is the queue. Engage with multiple NBs simultaneously if possible.

2. Prepare a complete submission package. Invest in thorough gap analysis before submitting. A complete, well-prepared application moves through review faster than a rushed one that generates rounds of clarification requests.

3. Conduct a mock review. Have an experienced regulatory consultant or former NB reviewer assess your technical documentation before submission. The cost of this review is negligible compared to the cost of a six-month delay caused by an incomplete filing.

4. Prioritize by deadline. If you have multiple devices, prioritize by transition deadline and revenue impact. IVDR Class C devices are the most urgent (May 26, 2026 deadline).

If You Are in the Review Queue

Priority: Proactive engagement.

1. Respond to clarification requests within 48 hours. Fast responses keep your application active. Slow responses push it to the back of the queue.

2. Designate a single point of contact for NB communication to ensure consistency and speed.

3. Prepare for the NB audit. Your QMS, manufacturing sites, and clinical evidence must be audit-ready at all times. Audit findings add months to the timeline.

4. Monitor your legacy certificate status. Track expiration dates carefully and ensure your transition timeline accounts for review duration.

If You Already Have MDR Certification

Priority: Plan for recertification now.

1. Begin recertification preparation 18 months before certificate expiry. The 13–18 month review timeline means you cannot afford to wait.

2. Update your technical documentation continuously rather than treating recertification as a one-time event. Keep clinical evaluations, PMS data, and PMCF results current.

3. Engage your Notified Body early to understand their recertification process and timeline expectations.

4. Prepare for EUDAMED. Ensure all device registrations, UDI data, and certificate information are accurate and current in the database.

The Readiness Gap

The 2026 survey reveals that the certification bottleneck is not purely a Notified Body capacity problem. It is equally a manufacturer readiness problem. The survey notes that Notified Bodies are "no longer simply reviewing whether a submission exists" — they are "assessing whether it is coherent, justified, complete, and ready to withstand challenge."

Certification is no longer about volume of documentation. It is about the quality of regulatory thinking behind it.

Manufacturers who invest in high-quality submissions — correct classification, complete clinical evidence, robust PMS plans, and audit-ready QMS — move through the pipeline faster. Those who submit voluminous but unfocused documentation get stuck in clarification loops.

What the Targeted Revisions Will Change (and Won't)

Will Change

• Certificate validity periods (removing five-year maximum)
• Surveillance audit frequency (extending from annual to potentially 24-month intervals)
• Scope of technical documentation review (reduced for medium-risk devices)
• Dispute resolution mechanisms (formalized ombudsperson role)

Won't Change

• The fundamental requirements of MDR/IVDR conformity assessment
• The need for comprehensive clinical evidence for high-risk devices
• The transition deadlines for legacy devices (unless specifically amended)
• The quality expectations for technical documentation

Won't Help With

• Immediate certification needs in 2026–2027 (the revisions won't take effect until 2027 at the earliest)
• The IVDR Class C May 2026 deadline
• EUDAMED compliance requirements

Financial Impact of Delays

For manufacturers facing certification gaps, the commercial consequences are severe:

• Loss of EU market access for affected products until certification is obtained
• Revenue disruption proportional to the EU revenue share of affected products
• Competitive disadvantage as certified competitors capture market share
• Supply chain disruption for downstream customers and healthcare providers
• Contract penalties for manufacturers with supply obligations tied to CE marking

Industry analyses consistently highlight that a majority of medical device startups fail before reaching market — with regulatory hurdles cited as a primary factor. The EU market is particularly challenging — a device cleared in weeks in the US can face 18+ month delays in Europe due to Notified Body backlogs.

Key Takeaways

1. The bottleneck is real and getting worse. Over 15,000 pending applications, 13–18 month review times, and converging deadlines create a crisis for EU market access.

2. Application quality matters more than ever. Notified Bodies are distinguishing between complete, well-prepared submissions and voluminous but unfocused documentation. Quality accelerates review; poor quality adds months.

3. IVDR Class C manufacturers have weeks, not months. The May 26, 2026 application deadline is imminent. Action is required now.

4. Recertification is the next wave. The first MDR certificates issued in 2021–2022 will need renewal starting in 2026–2027, creating a second peak in NB workload.

5. The targeted revisions will help, but not in time. The MDR/IVDR revisions are a structural improvement but won't take effect before 2027. Manufacturers must solve their immediate certification challenges under the current framework.

6. EUDAMED adds operational burden in May 2026. Plan for simultaneous EUDAMED compliance and certification work.